About Us

MISSION STATEMENT: The HIV+Hepatitis Policy Institute promotes quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions.

Monitors policies that impact the prevention and treatment of HIV, viral hepatitis, and other health conditions in the United States.

Communicates with members of the HIV, hepatitis, and other patient group communities on key policy issues that impact their access to healthcare.

Educates policymakers and members of the media about efforts to end both HIV and hepatitis in the United States and to improve access to quality and affordable healthcare for people with or at risk of serious or chronic health conditions.

Our Team

CARL SCHMID

Executive Director, HIV+Hepatitis Policy Institute, Washington, D.C.

cschmid@hivhep.org

Carl Schmid has been a national policy and advocacy leader in the HIV community for over 20 years.  He spent 16 years with The AIDS Institute, serving as its Deputy Executive Director. In December 2019, he formed the HIV+Hepatitis Policy Institute, which promotes quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions.

Mr. Schmid leads advocacy efforts to ensure domestic HIV and hepatitis programs are based on sound public policy and fully funded. He has expertise in healthcare financing systems, including Medicaid and Medicare, and leads efforts to ensure that the Affordable Care Act meets the needs of beneficiaries, including prescription medications.

In December 2018, he was appointed Co-Chair of the Presidential Advisory Council on HIV/AIDS (PACHA) and serves as a consumer representative to the National Association of Insurance Commissioners. 

He is a cancer survivor and living with chronic hepatitis B.

Mr. Schmid earned a B.A. in Public Affairs and an M.B.A. in International Affairs from the George Washington University in Washington, D.C.

Scott Palmer

Executive Assistant

spalmer@hivhep.org

Ann Lefert

The Lefert Group

Policy Consultant

ann@thelefertgroup.com

Jennifer Burke

Communications Consultant

jburke@hivhep.org

Board Members

CARL SCHMID

President

Executive Director

HIV+Hep Policy Institute

Washington, DC

REKHA RAMESH

Treasurer 

Executive Director, Policy

Gilead Sciences, Inc.

Foster City, CA

JUSTIN C. SMITH MS, MPH

Secretary

Director, Campaign to End AIDS

Positive Impact Health Centers

Atlanta, GA

JAMES CAREY

Head of U.S. Government Affairs and Policy

Organon and Co.

Washington, DC

MARC MEACHEM

Director of External Affairs

ViiV Healthcare

Washington, DC

RAFAELÉ NARVÁEZ

Co-Founder

Latinos Salud

Oakland Park, FL

ANDREW SPERLING

Director of Federal Legislative Advocacy

National Alliance on Mental Illness

Arlington, VA

PAM TRAXEL

Senior Vice President

American Cancer Society

Cancer Action Network

Washington, DC

STEVEN R. YOUNG

Former Director

HIV/AIDS Bureau, HRSA, HHS

Yardley, PA

Funders for HIV+Hepatitis Policy Institute

HIV+Hep appreciates the support of numerous funders, and recognizes those below that are our corporate members and sponsors:

Get Involved

Facebook posts by @HIV+Hep

Tweets by @HIV+Hep

1 hour ago
From @bloomberglaw, @HIVHep’s Carl Schmid on health plans & #ACA requirements to offer #PrEP w/o cost-sharing: “We want everyone to know it’s free. [If] it doesn’t say ‘zero cost-sharing,’ people may not know it. So we want to make it easy as possible”: https://t.co/KqhwlLpOCL.
20 hours ago
Should double charging patients for medication be legal? | Opinion https://t.co/NAkJ1dmpiH
23 hours ago
@HIVHep’s Carl Schmid praises the House-proposed FY22 funding increases for HIV programs but says the proposed + $5 million for @cdchep programs will not be nearly enough to achieve the president’s goal of eliminating #hepatitis by 2030: https://t.co/W7cVrIVmhZ. https://t.co/vPSueoXhlJ HIVHep photo
1 day ago
@HIVHep’s Carl Schmid lauded the federal govt issuing guidance that “associated services with #PrEP, such as provider visits & #HIV, #hepatitis, & STD testing along with other laboratory tests must be covered with no #patient cost-sharing”: https://t.co/9r4RVzmlvw. https://t.co/FNifYUgGAq HIVHep photo
2 days ago
Today, we, @HIVHep, and over 60 of the nation's leading HIV organizations demanded that @CDCgov reverse its decision to prohibit CDC prevention funds from paying for PrEP provider visits and lab tests 🧵 1/n https://t.co/kb9kHaAN1D

Pin It on Pinterest

Share This